View ValuationCynata Therapeutics 향후 성장Future 기준 점검 1/6Cynata Therapeutics 의 수익은 연간 50.4% 감소할 것으로 예상되는 반면, 연간 수익은 13.8% 로 증가할 것으로 예상됩니다. EPS는 연간 47.5% 만큼 쇠퇴할 것으로 예상됩니다.핵심 정보-50.4%이익 성장률-47.55%EPS 성장률Biotechs 이익 성장25.2%매출 성장률13.8%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트02 Apr 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 08Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: AUD 0.25 Discount Per Security: AUD 0.015 Transaction Features: Subsequent Direct Listing공시 • May 04Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: AUD 0.25 Transaction Features: Subsequent Direct Listing공시 • Dec 15Cynata Therapeutics Limited Completes Patient Enrolment in Phase 2 aGvHD Clinical TrialCynata Therapeutics Limited announced that patient enrolment has been completed in its Phase 2 clinical trial of CYP-001 in adults with newly diagnosed, high risk acute graft versus host disease (aGvHD). A total of 65 participants have been enrolled in the trial across numerous clinical centres in the US, Europe and Australia. Each participant was randomised to receive either steroids plus CYP-001, or steroids plus placebo. The trial involves a 100-day primary evaluation period, which is expected to conclude in March 2026, with results anticipated around June 2026. The primary endpoint is Overall Response Rate at Day 28. In a successful Phase 1 trial in patients with SR-aGvHD, 87% of patients showed an Overall Response, 53% showed a Complete Response, and 60% survival for at least two years. Importantly, there were no serious adverse events or safety concerns related to CYP-001 treatment. This ground-breaking trial led to two publications in the prestigious journal Nature Medicine. CYP-001 has been granted Orphan Drug Designation by the US FDA for the treatment of aGvHD.공시 • Sep 18Cynata Therapeutics Limited, Annual General Meeting, Nov 13, 2025Cynata Therapeutics Limited, Annual General Meeting, Nov 13, 2025.공시 • Apr 07Cynata Therapeutics Limited Announces Positive Efficacy Data Observed in Preclinical Studies Conducted with Cymerus Ipsc1-Derived Mscs in Models of Ischaemic Heart DiseaseCynata Therapeutics Limited announced positive efficacy data observed in preclinical studies conducted with Cynata's Cymerus™? iPSC-derived MSCs in models of ischaemic heart disease. MSCs have the potential to treat ischaemic heart disease, the leading cause of death worldwide, by releasing proteins and other bioactive molecules. This project evaluated a new, minimally invasive method to deliver beneficial molecules from MSCs over an extended period, using a retrievable encapsulation device. The device, which can be implanted under the skin, protects the cells while still permitting the release of molecules into the circulation. Key Highlights. In a rat model of heart attack (known as an ischaemia-reperfusion model), treatment with encapsulated Cymerus™? MSCs resulted in the following: Significantly improved heart function and a reduction in harmful structural changes in the heart, compared to controls treated with encapsulated placebo. Less heart muscle thickening, smaller scar tissue, and fewer fibrous tissue buildups. Encapsulated Cymerus MSCs were still alive and functional twelve weeks after implantation. Cymerus™? M SCs produce proteins that support tissue health, aid in healing, help to protect cells from damage, play a role in regulating the immune system and reduce inflammation. In an in vitro model of human heart tissues created and grown in a laboratory (known as "cardiac spheroids"), tissues treated with proteins from Cymerus™? Mscs showed improved survival and function compared to controls treated with placebo. Chief Investigator of the study, Associate Professor Shiang (Max) Lim (Head, Cardiac Regeneration Laboratory, St Vincent's Institute of Medical Research, Melbourne) said: This study demonstrates the utility of a clinically viable, minimally invasive method for sustained delivery of active molecules released by Cymerus™? MScs, which has the potential to address a major gap in the treatment of ischaemic heart disease".공시 • Jan 23Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 8.115 million.Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 8.115 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,444,445 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 638,886 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Transaction Features: Subsequent Direct Listing공시 • Dec 06Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 8.115 million.Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 8.115 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,444,445 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 638,886 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Transaction Features: Subsequent Direct Listing공시 • Sep 24Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024.공시 • Apr 09Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical TrialCynata Therapeutics Limited announced the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). CYP-006TK is Cynata's Cymerus iPSC-derived MSC topical wound dressing product candidate, which comprises MSCs seeded onto a novel silicon dressing. Due to reduced blood flow, patients with diabetes are at risk of developing non-healing wounds on the feet/lower limbs, which are also known as DFU. In addition to causing severe pain and discomfort, DFU pose a significant risk of infection, and if therapy is unsuccessful, amputation may be necessary. In this trial, CYP-006TK is being investigated as a potential treatment to promote wound healing in patients with DFU. The pre-specified sample size has now been reached, with a total of 30 patients with DFU randomised on a 1:1 basis to receive either: (i) CYP-006TK treatment for four weeks, followed by standard of care treatment for the rest of the study; or (ii) standard of care treatment throughout the study. In accordance with the study protocol, patients will be followed for 24 weeks following treatment initiation, which means that the last patient visit in this trial is expected to occur around September 2024.공시 • Mar 06Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001Cynata Therapeutics Limited confirmed that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD). CYP-001 is Cynata's Cymerus™ off-the-shelf iPSC[1]-derived MSC[2] product candidate for intravenous infusion, which previously generated very encouraging safety and efficacy results in a Phase 1 clinical trial in steroid-resistant aGvHD. The US FDA has cleared an Investigational New Drug (IND) application for CYP-001 and granted the product Orphan Drug Designation[4] for the treatment of aGvHD. aGvHD is a potentially life-threatening complication of bone marrow transplants or similar procedures. It arises when immune cells in the transplant (the graft) attack the recipient's tissues (the host) as "foreign". In this trial, CYP-001 is being investigated as a potential immune modulating treatment for aGvHD. This global Phase 2 trial aims to enrol approximately 60 patients with high-risk aGvHD, who will be randomised to receive either steroids plus CYP-001, or steroids plus placebo. Additional details on the trial may be found at clinicaltrials.gov using identifier NCT05643638. The trial has been approved to commence in Australia, the USA and Turkey, and numerous clinical centres across those jurisdictions are now open for recruitment. The first patient was enrolled in the USA.공시 • Oct 11Cynata Therapeutics Limited Announces Resignation of David Atkins as DirectorCynata Therapeutics Limited that Dr. David Atkins has informed the Board that he will not be standing for re-election as a Director at the Company's Annual General Meeting (AGM) to be held on 13 November 2023 and accordinglywill cease to be a Director from the conclusion of the AGM.공시 • Jun 30+ 1 more updateCynata Therapeutics Limited Announces Management AppointmentsCynata Therapeutics Limited announced the appointment of Dr. Kilian Kelly to the position of Managing Director, effective 1 July 2023, following the retirement of Dr. Ross Macdonald. Dr. Kelly has been Cynata's Chief Operating Officer since May 2019 and has been instrumental in advancing the Company's clinical pipeline since joining Cynata as Vice President, Product Development in 2014. The company is also pleased to welcome Dr. David Atkins to the Board of Directors. Dr. Atkins is the Managing Partner of BioScience Managers, an international healthcare investment firm and a major Cynata shareholder. Dr. Stewart Washer will step down from his position as a non-executive director. Dr. Atkins has over 25 years' experience as a global leader in a broad range of life science and healthcare businesses including Johnson & Johnson and Danaher. He has held senior leadership positions in R&D, business development, operations and sales and marketing. David has extensive commercial experience in markets in North America, EMEA, Asia and Latin America. Furthermore, David has founded or assumed leadership roles in 3 start-up businesses in gene therapy, molecular and cellular cancer diagnostics and clinical genomics. Given Dr. Atkins' executive role with Bioscience Managers (a substantial holder of Cynata), the Board considers that Dr. Atkins is not an independent director.공시 • Jan 30Cynata Therapeutics Limited Receives IRB Approval for Proposed aGvHD Phase 2 Clinical TrialCynata Therapeutics Limited has announced that it has received approval to commence the proposed phase 2 clinical trial in acute graft-versus-host disease (aGvHD) from Advarra Inc., a central Institutional Research Board (IRB) service provider in the USA. IRB approval is an essential step in the process of opening clinical study sites and to commencing a clinical trial in humans in the United States. Cynata is now finalising contractual and logistic arrangements with individual sites (hospitals) to prepare for patient recruitment. This follows the landmark clearance of Cynata's Investigational New Drug (IND) application in 2022 and grant of Orphan Drug Status for CYP-001. The proposed clinical trial is titled "A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase 2 Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vsCorticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease" and is expected to be conducted in around 60 patients at sites in the United States, Europe and Australia.공시 • Jan 09Cynata Therapeutics Limited Receives Notice of Acceptance from IP Australia for Novel Application of Cymerus MSCsCynata Therapeutics Limited has announced that a Notice of Acceptance has been received from IP Australia, the intellectual property office of the Australian Government, for a patent application covering its proprietary CymerusTM mesenchymal stem cell (MSC) platform technology. The patent application entitled "Method for Treating Allergic Airways Disease (AAD)/Asthma" is wholly owned by Cynata and describes a novel method of use of Cynata's proprietary Cymerus MSC products in treating diseases of the lungs and airways. The Notice of Acceptance is sent to the applicant when IP Australia intends to issue a patent. The patent adds to the existing broad and comprehensive IP protection of the Cymerus platform and its unique ability to yield highly consistent MSCs at scale, from a single donation, to create therapeutic stem cell products. Cynata anticipates that the patent will be granted around mid-March 2023, with an expiration date of 31 August 2038.이익 및 매출 성장 예측OTCPK:CYYN.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/20283-26-27-2716/30/20272-15-15-1516/30/20262-8-8-8112/31/20252-8-8-8N/A9/30/20252-9-8-8N/A6/30/20252-9-9-9N/A3/31/20252-9-8-8N/A12/31/20242-9-8-8N/A9/30/20242-9-9-9N/A6/30/20242-10-10-10N/A3/31/20242-12-11-11N/A12/31/20232-14-12-12N/A9/30/20232-14-13-13N/A6/30/20232-14-14-14N/A3/31/20232-12-12-12N/A12/31/20223-9-10-10N/A9/30/20225-7-7-7N/A6/30/20228-5-3-3N/A3/31/20228-5-2-2N/A12/31/20218-4-1-1N/A9/30/20215-6-3-3N/A6/30/20212-8-5-5N/A3/31/20212-7-5-5N/A12/31/20203-6-5-5N/A9/30/20205-5-4-4N/A6/30/20207-4-3-3N/A3/31/20206-6-5-5N/A12/31/20194-8-7-7N/A9/30/20193-8N/A-7N/A6/30/20191-8N/A-7N/A3/31/20191-7N/A-6N/A12/31/20181-6N/A-5N/A9/30/20181-5N/A-4N/A6/30/20181-5N/A-4N/A3/31/20181-5N/A-4N/A12/31/20171-5N/A-5N/A9/30/20172-5N/A-4N/A6/30/20172-5N/A-4N/A3/31/20172-4N/A-3N/A12/31/20162-3N/A-2N/A9/30/20161-4N/A-3N/A6/30/20161-5N/A-4N/A3/31/20161-5N/A-4N/A12/31/20151-5N/A-4N/A9/30/20151-4N/A-4N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: CYYN.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: CYYN.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: CYYN.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: CYYN.F 의 수익(연간 13.8%)이 US 시장(연간 12.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: CYYN.F 의 수익(연간 13.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: CYYN.F의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/30 18:26종가2026/06/30 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cynata Therapeutics Limited는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Darren VincentShaw and Partners LimitedNicholas LauTaylor Collison Limited
공시 • May 08Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: AUD 0.25 Discount Per Security: AUD 0.015 Transaction Features: Subsequent Direct Listing
공시 • May 04Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: AUD 0.25 Transaction Features: Subsequent Direct Listing
공시 • Dec 15Cynata Therapeutics Limited Completes Patient Enrolment in Phase 2 aGvHD Clinical TrialCynata Therapeutics Limited announced that patient enrolment has been completed in its Phase 2 clinical trial of CYP-001 in adults with newly diagnosed, high risk acute graft versus host disease (aGvHD). A total of 65 participants have been enrolled in the trial across numerous clinical centres in the US, Europe and Australia. Each participant was randomised to receive either steroids plus CYP-001, or steroids plus placebo. The trial involves a 100-day primary evaluation period, which is expected to conclude in March 2026, with results anticipated around June 2026. The primary endpoint is Overall Response Rate at Day 28. In a successful Phase 1 trial in patients with SR-aGvHD, 87% of patients showed an Overall Response, 53% showed a Complete Response, and 60% survival for at least two years. Importantly, there were no serious adverse events or safety concerns related to CYP-001 treatment. This ground-breaking trial led to two publications in the prestigious journal Nature Medicine. CYP-001 has been granted Orphan Drug Designation by the US FDA for the treatment of aGvHD.
공시 • Sep 18Cynata Therapeutics Limited, Annual General Meeting, Nov 13, 2025Cynata Therapeutics Limited, Annual General Meeting, Nov 13, 2025.
공시 • Apr 07Cynata Therapeutics Limited Announces Positive Efficacy Data Observed in Preclinical Studies Conducted with Cymerus Ipsc1-Derived Mscs in Models of Ischaemic Heart DiseaseCynata Therapeutics Limited announced positive efficacy data observed in preclinical studies conducted with Cynata's Cymerus™? iPSC-derived MSCs in models of ischaemic heart disease. MSCs have the potential to treat ischaemic heart disease, the leading cause of death worldwide, by releasing proteins and other bioactive molecules. This project evaluated a new, minimally invasive method to deliver beneficial molecules from MSCs over an extended period, using a retrievable encapsulation device. The device, which can be implanted under the skin, protects the cells while still permitting the release of molecules into the circulation. Key Highlights. In a rat model of heart attack (known as an ischaemia-reperfusion model), treatment with encapsulated Cymerus™? MSCs resulted in the following: Significantly improved heart function and a reduction in harmful structural changes in the heart, compared to controls treated with encapsulated placebo. Less heart muscle thickening, smaller scar tissue, and fewer fibrous tissue buildups. Encapsulated Cymerus MSCs were still alive and functional twelve weeks after implantation. Cymerus™? M SCs produce proteins that support tissue health, aid in healing, help to protect cells from damage, play a role in regulating the immune system and reduce inflammation. In an in vitro model of human heart tissues created and grown in a laboratory (known as "cardiac spheroids"), tissues treated with proteins from Cymerus™? Mscs showed improved survival and function compared to controls treated with placebo. Chief Investigator of the study, Associate Professor Shiang (Max) Lim (Head, Cardiac Regeneration Laboratory, St Vincent's Institute of Medical Research, Melbourne) said: This study demonstrates the utility of a clinically viable, minimally invasive method for sustained delivery of active molecules released by Cymerus™? MScs, which has the potential to address a major gap in the treatment of ischaemic heart disease".
공시 • Jan 23Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 8.115 million.Cynata Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 8.115 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,444,445 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 638,886 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Transaction Features: Subsequent Direct Listing
공시 • Dec 06Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 8.115 million.Cynata Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 8.115 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,444,445 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 638,886 Price\Range: AUD 0.18 Discount Per Security: AUD 0.0108 Transaction Features: Subsequent Direct Listing
공시 • Sep 24Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024.
공시 • Apr 09Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical TrialCynata Therapeutics Limited announced the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). CYP-006TK is Cynata's Cymerus iPSC-derived MSC topical wound dressing product candidate, which comprises MSCs seeded onto a novel silicon dressing. Due to reduced blood flow, patients with diabetes are at risk of developing non-healing wounds on the feet/lower limbs, which are also known as DFU. In addition to causing severe pain and discomfort, DFU pose a significant risk of infection, and if therapy is unsuccessful, amputation may be necessary. In this trial, CYP-006TK is being investigated as a potential treatment to promote wound healing in patients with DFU. The pre-specified sample size has now been reached, with a total of 30 patients with DFU randomised on a 1:1 basis to receive either: (i) CYP-006TK treatment for four weeks, followed by standard of care treatment for the rest of the study; or (ii) standard of care treatment throughout the study. In accordance with the study protocol, patients will be followed for 24 weeks following treatment initiation, which means that the last patient visit in this trial is expected to occur around September 2024.
공시 • Mar 06Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001Cynata Therapeutics Limited confirmed that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD). CYP-001 is Cynata's Cymerus™ off-the-shelf iPSC[1]-derived MSC[2] product candidate for intravenous infusion, which previously generated very encouraging safety and efficacy results in a Phase 1 clinical trial in steroid-resistant aGvHD. The US FDA has cleared an Investigational New Drug (IND) application for CYP-001 and granted the product Orphan Drug Designation[4] for the treatment of aGvHD. aGvHD is a potentially life-threatening complication of bone marrow transplants or similar procedures. It arises when immune cells in the transplant (the graft) attack the recipient's tissues (the host) as "foreign". In this trial, CYP-001 is being investigated as a potential immune modulating treatment for aGvHD. This global Phase 2 trial aims to enrol approximately 60 patients with high-risk aGvHD, who will be randomised to receive either steroids plus CYP-001, or steroids plus placebo. Additional details on the trial may be found at clinicaltrials.gov using identifier NCT05643638. The trial has been approved to commence in Australia, the USA and Turkey, and numerous clinical centres across those jurisdictions are now open for recruitment. The first patient was enrolled in the USA.
공시 • Oct 11Cynata Therapeutics Limited Announces Resignation of David Atkins as DirectorCynata Therapeutics Limited that Dr. David Atkins has informed the Board that he will not be standing for re-election as a Director at the Company's Annual General Meeting (AGM) to be held on 13 November 2023 and accordinglywill cease to be a Director from the conclusion of the AGM.
공시 • Jun 30+ 1 more updateCynata Therapeutics Limited Announces Management AppointmentsCynata Therapeutics Limited announced the appointment of Dr. Kilian Kelly to the position of Managing Director, effective 1 July 2023, following the retirement of Dr. Ross Macdonald. Dr. Kelly has been Cynata's Chief Operating Officer since May 2019 and has been instrumental in advancing the Company's clinical pipeline since joining Cynata as Vice President, Product Development in 2014. The company is also pleased to welcome Dr. David Atkins to the Board of Directors. Dr. Atkins is the Managing Partner of BioScience Managers, an international healthcare investment firm and a major Cynata shareholder. Dr. Stewart Washer will step down from his position as a non-executive director. Dr. Atkins has over 25 years' experience as a global leader in a broad range of life science and healthcare businesses including Johnson & Johnson and Danaher. He has held senior leadership positions in R&D, business development, operations and sales and marketing. David has extensive commercial experience in markets in North America, EMEA, Asia and Latin America. Furthermore, David has founded or assumed leadership roles in 3 start-up businesses in gene therapy, molecular and cellular cancer diagnostics and clinical genomics. Given Dr. Atkins' executive role with Bioscience Managers (a substantial holder of Cynata), the Board considers that Dr. Atkins is not an independent director.
공시 • Jan 30Cynata Therapeutics Limited Receives IRB Approval for Proposed aGvHD Phase 2 Clinical TrialCynata Therapeutics Limited has announced that it has received approval to commence the proposed phase 2 clinical trial in acute graft-versus-host disease (aGvHD) from Advarra Inc., a central Institutional Research Board (IRB) service provider in the USA. IRB approval is an essential step in the process of opening clinical study sites and to commencing a clinical trial in humans in the United States. Cynata is now finalising contractual and logistic arrangements with individual sites (hospitals) to prepare for patient recruitment. This follows the landmark clearance of Cynata's Investigational New Drug (IND) application in 2022 and grant of Orphan Drug Status for CYP-001. The proposed clinical trial is titled "A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase 2 Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vsCorticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease" and is expected to be conducted in around 60 patients at sites in the United States, Europe and Australia.
공시 • Jan 09Cynata Therapeutics Limited Receives Notice of Acceptance from IP Australia for Novel Application of Cymerus MSCsCynata Therapeutics Limited has announced that a Notice of Acceptance has been received from IP Australia, the intellectual property office of the Australian Government, for a patent application covering its proprietary CymerusTM mesenchymal stem cell (MSC) platform technology. The patent application entitled "Method for Treating Allergic Airways Disease (AAD)/Asthma" is wholly owned by Cynata and describes a novel method of use of Cynata's proprietary Cymerus MSC products in treating diseases of the lungs and airways. The Notice of Acceptance is sent to the applicant when IP Australia intends to issue a patent. The patent adds to the existing broad and comprehensive IP protection of the Cymerus platform and its unique ability to yield highly consistent MSCs at scale, from a single donation, to create therapeutic stem cell products. Cynata anticipates that the patent will be granted around mid-March 2023, with an expiration date of 31 August 2038.